Eventide Asset Management, LLC Allakos Inc. Transaction History

Eventide Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $457,626 - $883,724	-90,084 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $4.62 Million - $60.4 Million	-539,916 Reduced 85.7%	90,084 $882,000
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $17.5 Million - $25.3 Million	229,000 Added 57.11%	630,000 $66.7 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $7.17 Million - $9.58 Million	84,000 Added 26.5%	401,000 $34.2 Million
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $12.5 Million - $23.9 Million	157,000 Added 98.13%	317,000 $44.4 Million
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $7.12 Million - $14.9 Million	160,000 New	160,000 $7.12 Million
Q4 2018 Feb 14, 2019	SELL	$31.59 - $62.65 $1.11 Million - $2.19 Million	-35,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$31.25 - $47.64 $1.09 Million - $1.67 Million	35,000 New	35,000 $1.58 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $98.3M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.